Get the Stockscreener App
2.39
0.42%
-0.010
After Hours:
2.35
-0.04
-1.67%
Cytomx Therapeutics Inc stock is traded at $2.39, with a volume of 1.33M.
It is down -0.42% in the last 24 hours and up +6.22% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$2.40
Open:
$2.4
24h Volume:
1.33M
Relative Volume:
0.28
Market Cap:
$192.68M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-119.50
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
+0.42%
1M Performance:
+6.22%
6M Performance:
+181.11%
1Y Performance:
+59.33%
1-Day Range:
$2.35
$2.41
1-Week Range:
$2.32
$2.47
52-Week Range:
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.39 | 378.11M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
What are analysts’ price targets for CytomX Therapeutics Inc. in the next 12 monthsFree Wealth Planning Blueprint - jammulinksnews.com
What institutional investors are buying CytomX Therapeutics Inc. stockGet expert analysis on top stock picks - jammulinksnews.com
How strong is CytomX Therapeutics Inc. company’s balance sheetNavigate market volatility with smart strategies - jammulinksnews.com
What makes CytomX Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - metal.it
What drives CytomX Therapeutics Inc. stock priceStrong return on assets - PrintWeekIndia
CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate - Yahoo Finance
What analysts say about CytomX Therapeutics Inc. stockSkyrocketing returns - PrintWeekIndia
CytomX Therapeutics Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional
10 Best Performing Penny Stocks So Far in 2025 - Insider Monkey
Is CytomX Therapeutics Inc. a good long term investmentFree Stock Market Return Analysis - Autocar Professional
Why CytomX Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser
How CytomX Therapeutics Inc. stock performs during market volatilityProtected Capital Trading Plan - Newser
The Future of Allogene Therapeutics Inc: Analyzing ALLO - investchronicle.com
Pliant Therapeutics Inc (PLRX) Stock: Navigating a Year of Volatility - investchronicle.com
CTMX SEC FilingsCytomx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Do CytomX Therapeutics' (NASDAQ:CTMX) Earnings Warrant Your Attention? - Yahoo Finance
CytomX Q2 2025 presentation slides: CX-2051 shows promising Phase 1 results in CRC By Investing.com - Investing.com South Africa
CytomX Q2 2025 presentation slides: CX-2051 shows promising Phase 1 results in CRC - Investing.com
Certain Pre-Funded warrants of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JUN-2025. - MarketScreener
CytomX Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
CytomX Therapeutics CEO Sells Shares to Meet Tax Obligations - TradingView
CytomX Therapeutics Approves Key Amendments at Annual Meeting - TipRanks
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):